Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Valeant Appoints EVP, CFO | Contract Pharma
Breaking News, Promotions & Moves

Valeant Appoints EVP, CFO

Rosiello brings 30 years of experience in the healthcare sector

Robert L. Rosiello has been appointed executive vice president, Valeant Pharmaceuticals, and will take over the role of chief financial officer effective July 1. He succeeds Howard Schiller as CFO, who will remain on Valeant’s Board and serve as a consultant.
 
Mr. Rosiello spent 30 years with McKinsey & Company working with healthcare, technology and consumer companies to deliver growth through M&A and financial performance improvement. As Senior Partner in charge of the global merger practice for the past decade, Mr. Rosiello led M&A integrations for pharmaceutical, specialty pharmaceutical and medical device companies in the U.S., Europe and Asia.
 
“The Board and I are delighted that Rob has agreed to join Valeant,” said J. Michael Pearson, chairman and chief executive officer. “Rob is someone I have worked closely with for 20 years. I know his tremendous expertise in healthcare and in particular M&A, his unquestioned intellect, and work ethic and integrity will prove to be of great value to the Valeant organization and its shareholders. I want to thank Howard for his strong leadership to both myself and the entire organization these past few years and I will continue to rely on his valuable counsel as a member of our Board of Directors.”
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters